Published in Proc Natl Acad Sci U S A on May 11, 1999
Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood | NCT02533895
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest (2002) 3.41
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res (2012) 1.53
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res (2008) 1.36
Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol (2008) 1.19
Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med (2004) 1.15
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A (2001) 1.14
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res (2000) 1.12
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res (2009) 1.01
The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics (2006) 1.00
All in the head: obstacles for immune rejection of brain tumours. Immunology (2002) 0.99
Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther (2009) 0.95
Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol Res (2008) 0.94
Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother (2010) 0.90
Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives. Springer Semin Immunopathol (2005) 0.89
Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res (2014) 0.86
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. Mol Ther (2014) 0.86
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. J Virol (2004) 0.82
Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news? Br J Cancer (2003) 0.77
Progress in cancer vaccines by enhanced self-presentation. Proc Natl Acad Sci U S A (2001) 0.75
In vivo histone H1 migration from necrotic to viable tissue. Oncotarget (2017) 0.75
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother (2016) 0.75
Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines (Basel) (2015) 0.75
Safety of targeting tumor endothelial cell antigens. J Transl Med (2016) 0.75
Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidity. Immunology (2001) 0.75
Immune balance: the development of the idea and its applications. J Hist Biol (2014) 0.75
Novel vaccines for glioblastoma: clinical update and perspective. Immunotherapy (2016) 0.75
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (1994) 3.96
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science (1998) 3.68
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol (1996) 3.11
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
CD4 T cells and their role in antitumor immune responses. J Exp Med (1999) 2.27
Cancer vaccines. Nat Med (1998) 2.22
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A (1994) 1.91
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med (1999) 1.70
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med (1999) 1.58
Induction of anti-self-immunity to cure cancer. Cell (1995) 1.54
Unique tumor-specific antigens. Annu Rev Immunol (1988) 1.33
Molecular mimicry between non-self, modified self and self in autoimmunity. Semin Immunol (1998) 0.94
Self-determinant selection and selective regulation. Chem Immunol (1995) 0.82
Releasing the brakes on antitumor immune response. Science (1996) 0.81
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science (1989) 4.19
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature (1987) 3.96
A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78
Molecular and cellular events of T cell development. Adv Immunol (1989) 3.50
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91
Deletion of self-reactive thymocytes occurs at a CD4+8+ precursor stage. Nature (1988) 2.84
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med (1998) 2.69
Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci U S A (1987) 2.57
Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity (1999) 2.55
Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes. Science (1986) 2.40
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 2.13
Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10
Effects of cyclosporine A on T cell development and clonal deletion. Science (1988) 2.08
T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev (1987) 2.07
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01
Differential expression of two distinct T-cell receptors during thymocyte development. Nature (1987) 1.95
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A (1998) 1.95
The fate of CD4-8- T cell receptor-alpha beta+ thymocytes. J Immunol (1991) 1.90
Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90
In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity (1996) 1.89
Localization of SV40 genes within supercoiled loop domains. Nucleic Acids Res (1980) 1.68
Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther (1999) 1.63
Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. N Engl J Med (1987) 1.63
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Tumour antigens. A new look for the 1990s. Nature (1994) 1.56
CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med (2000) 1.48
A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med (1995) 1.44
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer (1998) 1.38
In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol (2000) 1.36
The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul (1978) 1.23
Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol (1994) 1.17
Sequence analysis of nuclear matrix associated DNA from rat liver. Exp Cell Res (1980) 1.17
Early genetic events in T cell development analyzed by in situ hybridization. J Exp Med (1987) 1.16
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med (1996) 1.13
Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther (1998) 1.08
Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine (2000) 1.08
Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3. J Immunol (1988) 1.04
The unfolding story of T cell receptor gamma. FASEB J (1987) 1.04
Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res (1993) 1.03
Activation properties of T cell receptor-gamma delta hybridomas expressing diversity in both gamma- and delta-chains. J Immunol (1988) 1.03
Molecular mechanisms for lineage commitment in T cell development. Semin Immunol (1990) 0.98
Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol (1996) 0.97
Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan. Transplantation (1993) 0.94
Cyclosporin A inhibits positive selection and delays negative selection in alpha beta TCR transgenic mice. J Immunol (1994) 0.94
Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol (1998) 0.94
Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood (1991) 0.93
Murine tumor antigens: is it worth the search? Curr Opin Immunol (1996) 0.91
Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res (2001) 0.91
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol (2001) 0.89
Immunoglobulin gene rearrangements in remission bone marrow specimens from patients with acute lymphoblastic leukemia. Blood (1986) 0.89
T cell receptor gamma/delta chain diversity. J Exp Med (1988) 0.89
Aplastic crisis due to extensive bone marrow necrosis in sickle cell disease. Arch Intern Med (1982) 0.89
Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem (1995) 0.88
Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats. Stroke (1997) 0.88
Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer (2000) 0.85
Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother Emphasis Tumor Immunol (1996) 0.84
High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res (1993) 0.84
Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther (2001) 0.83
An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin. J Immunol (2001) 0.83
Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res (1999) 0.83
Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther (1999) 0.81
Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J Neurosurg (2000) 0.81
Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods (1997) 0.81
Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. J Hepatol (2000) 0.80
Homozygous alpha thalassemia/Hb G Philadelphia. Hemoglobin (1982) 0.79
Selective association between MHC class I-restricted T cell receptors, CDS, and activated tyrosine kinases on thymocytes undergoing positive selection. J Immunol (1992) 0.79
A murine thymocyte clone expressing gamma delta T cell receptor mediates natural killer-like cytolytic function and TH1-like lymphokine production. Cell Immunol (1990) 0.79
Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor. J Surg Oncol (1999) 0.78
Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother (1991) (1992) 0.78
Can bone marrow-derived thymic stromal cells mediate the positive selection of class I-restricted T cells? Cell Immunol (1996) 0.78
Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol (1995) 0.78
Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer. Laryngoscope (1999) 0.78
Self-reactive T cells are present in the peripheral lymphoid tissues of cyclosporin A-treated mice. Int Immunol (1992) 0.77
Comparative analysis of paracrine immunotherapy in experimental brain tumors. Neurosurg Focus (2000) 0.77
Are the IL-2 receptors expressed in the murine fetal thymus functional? Dev Immunol (1990) 0.77
Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J Immunother (2000) 0.77
The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy. Immunol Res (1993) 0.75
Tyrosine kinase triggering in thymocytes undergoing positive selection. Eur J Immunol (1992) 0.75
Gene therapy: its potential applications in the treatment of renal-cell carcinoma. Semin Oncol (1995) 0.75